Summary
23andMe will continue its DNA testing services following its acquisition by Regeneron Pharmaceuticals for $256 million after a bankruptcy auction. While the deal requires compliance with privacy laws regarding customer data, concerns remain about how much genetic information may be retained by Regeneron. The acquisition, expected to close pending US Bankruptcy Court approval, aims to enhance Regeneron’s genetics research initiatives, with assurances that customer privacy will be maintained and all employees will retain their positions.
Loading PerspectiveSplit analysis...
